Overview
- Celtarys unveiled the commercial kit in a public presentation in Santiago on Tuesday and said the system can run assays in a single day while cutting preclinical characterization costs by up to 80 percent.
- The kit includes fluorescent ligands, reagents, controls, plates and a QR-linked validated protocol so conventional labs can run live-cell binding and competition tests without specialized radioactive facilities.
- The company was founded in 2021 as a Universidade de Santiago de Compostela spin-off and now has about ten staff, more than 40 clients in 14 countries, collaborations with centres such as MD Anderson and Institut Curie, and over €2 million in public competitive funding.
- Celtarys is prioritizing applications for protein degraders including PROTACs, a class of drugs that tag disease-linked proteins for destruction and where precise early assays help pick promising candidates for costly clinical work.
- The firm’s performance claims are company-reported and will require independent benchmarking and wider adoption before they change standard industry practice, but successful validation could reduce outsourcing, lower costs for researchers, and speed which candidates move toward clinical trials.